Ascendis Pharma A/S
ASNDDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Jun 16, 2026
4dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Conference
Ascendis Pharma announced it will present data from three rare endocrine disease programs at ENDO 2026 conference in Chicago, including two oral presentations and three posters on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency.
Source1 more catalyst beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon CNP
Achondroplasia
Lonapegsomatropin
Growth Hormone Deficiency
TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon IL-2 β/γ
Advanced Solid Tumor
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
ACP-001
Growth Hormone Deficiency (GHD)
Navepegritide
Achondroplasia
Somatropin
Turner Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency | - | - |
TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor | - | - |
ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency | - | - |
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia | - | - |
ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Somatropin | Phase 2 | Turner Syndrome | - | - |
Achondroplasia
3 drugs in this indication
Growth Hormone Deficiency (GHD)
1 drug in this indication
Adult Growth Hormone Deficiency
1 drug in this indication
Growth Hormone Deficiency, Pediatric
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)